85 related articles for article (PubMed ID: 17442615)
1. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.
Suzuki F; Akuta N; Suzuki Y; Yatsuji H; Sezaki H; Arase Y; Kawamura Y; Hosaka T; Kobayashi M; Ikeda K; Kobayashi M; Watahiki S; Kumada H
J Clin Virol; 2007 Jun; 39(2):149-52. PubMed ID: 17442615
[No Abstract] [Full Text] [Related]
2. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of the therapeutical effects of entecavir and lamvudine in treatment of HBeAg-positive chronic hepatitis B].
Hou HB; Deng LN; Li CP; Liu XR; Liu FQ
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):873-4. PubMed ID: 19958652
[No Abstract] [Full Text] [Related]
4. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient.
Guo JJ; Li QL; Shi XF; Zhang DZ; Zeng AZ; Feng T; Huang AL
Antiviral Res; 2009 Feb; 81(2):180-3. PubMed ID: 18948142
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
Jardi R; Rodriguez-Frias F; Schaper M; Ruiz G; Elefsiniotis I; Esteban R; Buti M
J Viral Hepat; 2007 Dec; 14(12):835-40. PubMed ID: 18070286
[TBL] [Abstract][Full Text] [Related]
6. [Entecavir--close perspective for using it].
Halota W; Pawłowska M
Przegl Epidemiol; 2006; 60(1):115-8. PubMed ID: 16758749
[TBL] [Abstract][Full Text] [Related]
7. [Emergence of entecavir genotypic resistance in a nucleoside naive chronic hepatitis B patient who had been treated for nearly five years: a case report].
Liu F; Wang XW
Zhonghua Gan Zang Bing Za Zhi; 2013 Oct; 21(10):781-2. PubMed ID: 24579214
[No Abstract] [Full Text] [Related]
8. Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?
Zoulim F
Hepatology; 2006 Dec; 44(6):1404-7. PubMed ID: 17133478
[No Abstract] [Full Text] [Related]
9. [Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].
Ma H; Ren JB; Li HY; Wang Y; Wang RL; Liang L; Sun SJ; Jia JD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):102-4. PubMed ID: 17653304
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
11. [Evolution of hepatitis B virus quasispecies during lamivudine-entecavir sequential therapy].
Liu L; Tang YZ; Li JG; Zhou JJ; Wang XH; Wang YM
Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):423-7. PubMed ID: 20587311
[TBL] [Abstract][Full Text] [Related]
12. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
13. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
Cheng PN; Chang TT
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
[TBL] [Abstract][Full Text] [Related]
14. Changing landscape of antiviral resistance management in chronic hepatitis B.
Nguyen T; Locarnini S; Desmond P
J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
[No Abstract] [Full Text] [Related]
15. Entecavir for chronic hepatitis B: a review.
Palumbo E
Ther Drug Monit; 2008 Feb; 30(1):1-4. PubMed ID: 18223455
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.
Baldick CJ; Eggers BJ; Fang J; Levine SM; Pokornowski KA; Rose RE; Yu CF; Tenney DJ; Colonno RJ
J Hepatol; 2008 Jun; 48(6):895-902. PubMed ID: 18362040
[TBL] [Abstract][Full Text] [Related]
17. Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV.
Jain MK; Zoellner CL
AIDS; 2007 Nov; 21(17):2365-6. PubMed ID: 18090296
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
[TBL] [Abstract][Full Text] [Related]
19. Entecavir: new drug. Chronic hepatitis B: a last resort.
Prescrire Int; 2007 Oct; 16(91):183-5. PubMed ID: 17926822
[TBL] [Abstract][Full Text] [Related]
20. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]